• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估囊性纤维化护理门诊费用的创新:爱尔兰和美国多学科护理中心的比较研究

Innovations in Evaluating Ambulatory Costs of Cystic Fibrosis Care: A Comparative Study Across Multidisciplinary Care Centers in Ireland and the United States.

作者信息

Brady Emma, Perkins Ryan C, Cullen Kate, Sawicki Gregory S, Kaplan Robert S, Doyle Gerardine

机构信息

Children's Health Ireland, Dublin, Ireland; PhD Student, UCD Michael Smurfit Graduate Business School, Blackrock, Ireland.

Division of Pulmonary Medicine, Boston Children's Hospital, Boston, Massachusetts, USA; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; Instructor in Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.

出版信息

NEJM Catal Innov Care Deliv. 2025 Feb;6(2). doi: 10.1056/CAT.24.0095. Epub 2025 Jan 15.

DOI:10.1056/CAT.24.0095
PMID:40171477
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11960789/
Abstract

Cystic fibrosis (CF) affects more than 160,000 individuals globally and has seen improved survival rates due to multidisciplinary care models and pharmacotherapy innovations. However, the associated costs remain substantial, prompting the authors to study and evaluate the expense of CF ambulatory care to understand how care structure influences costs. People with CF (PwCF) at large pediatric CF centers in both the United States and Ireland were recruited for parallel observational, prospective studies. Based upon the process of care, the lead clinicians at both sites identified and agreed on three strata of patients (0-11 months, 1-5 years, and 6-17 years of age). Process maps were developed for each of the age cohorts at each site, and the costs of ambulatory care - with emphasis on routine CF clinic visits - were measured utilizing time-driven activity-based costing (TDABC). A dollar-per-minute capacity cost rate (CCR) was calculated for all resources used in the care cycle. The total direct cost was obtained by multiplying the CCR for each resource by the time the resource was used during the patient's care cycle. The cost was summed across all resource types to obtain the cost over the entire care cycle for each site. Service operations were benchmarked to one site and variance analysis was performed. In total, 58 PwCF were included in the analysis (49 in the United States and 9 in Ireland); 4 were 0-11 months, 17 were 1-5 years, and 37 were 6-17 years of age. Physicians (United States) and respiratory consultants (Ireland) had the highest CCRs. Physicians and registered dietitians spent the most time with patients in the United States, compared with the clinical nurse specialists and dietitians in Ireland. The total variance in cost for clinical visits was largest in the 6- to 17-year-old group (28% variance, with 100% in the United States vs. 128% in Ireland). In the 6- to 17-year-old group, the largest drivers in total variance were quantity variance (variance in duration of time spent with patients), which was 108% greater in Ireland); the skill mix variance (variance in clinician type performing service for a given time), which was 49% greater in the United States; and the rate variance (variance in compensation levels across sites), which was 31% greater in the United States. The authors' use of TDABC to characterize the cost of multidisciplinary care during ambulatory clinic visits for PwCF, in combination with variance analysis (the quantitative investigation of the difference between actual and expected costs), provides new and innovative ways to compare costs across similar health care service delivery sites, providing insights into the distinctive features of each. A granular understanding of cost and comparison of resource utilization between centers provides valuable, organizationally relevant insights.

摘要

囊性纤维化(CF)在全球影响着超过16万人,由于多学科护理模式和药物治疗创新,其生存率有所提高。然而,相关成本仍然很高,促使作者研究和评估CF门诊护理的费用,以了解护理结构如何影响成本。美国和爱尔兰大型儿科CF中心的CF患者(PwCF)被招募进行平行的观察性前瞻性研究。根据护理流程,两个地点的首席临床医生确定并商定了三个患者分层(0至11个月、1至5岁和6至17岁)。为每个地点的每个年龄组制定了流程地图,并使用时间驱动作业成本法(TDABC)来衡量门诊护理的成本,重点是常规CF门诊就诊。计算了护理周期中使用的所有资源的每分钟容量成本率(CCR)。通过将每种资源的CCR乘以该资源在患者护理周期中使用的时间来获得总直接成本。将所有资源类型的成本相加,以获得每个地点整个护理周期的成本。将服务运营与一个地点进行基准比较并进行方差分析。总共有58名PwCF纳入分析(美国49名,爱尔兰9名);4名年龄在0至11个月,17名年龄在1至5岁,37名年龄在6至17岁。美国的医生和爱尔兰的呼吸顾问的CCR最高。与爱尔兰的临床护士专家和营养师相比,美国的医生和注册营养师与患者相处的时间最长。6至17岁年龄组临床就诊成本的总差异最大(差异率为28%,美国为100%,爱尔兰为128%)。在6至17岁年龄组中,总差异的最大驱动因素是数量差异(与患者相处时间的差异),爱尔兰的差异率高108%;技能组合差异(在给定时间内提供服务的临床医生类型的差异),美国的差异率高49%;以及费率差异(各地点薪酬水平的差异),美国的差异率高31%。作者使用TDABC来描述PwCF门诊就诊期间多学科护理的成本,并结合方差分析(对实际成本与预期成本之间差异的定量调查),提供了新的创新方法来比较类似医疗服务提供地点的成本,深入了解每个地点的独特特征。对成本的细致理解以及中心之间资源利用的比较提供了有价值的、与组织相关的见解。

相似文献

1
Innovations in Evaluating Ambulatory Costs of Cystic Fibrosis Care: A Comparative Study Across Multidisciplinary Care Centers in Ireland and the United States.评估囊性纤维化护理门诊费用的创新:爱尔兰和美国多学科护理中心的比较研究
NEJM Catal Innov Care Deliv. 2025 Feb;6(2). doi: 10.1056/CAT.24.0095. Epub 2025 Jan 15.
2
Do Orthopaedic Virtual Clinic Visits Demonstrate Cost and Time Efficiencies Compared With In-person Visits?骨科虚拟诊所就诊是否比亲自就诊更具成本和时间效率?
Clin Orthop Relat Res. 2023 Nov 1;481(11):2080-2090. doi: 10.1097/CORR.0000000000002813. Epub 2023 Aug 25.
3
Endoscopic Versus Open Carpal Tunnel Release: A Detailed Analysis Using Time-Driven Activity-Based Costing at an Academic Medical Center.内镜下与开放性腕管松解术:在一所学术医疗中心使用基于时间驱动作业成本法的详细分析
J Hand Surg Am. 2019 Jan;44(1):62.e1-62.e9. doi: 10.1016/j.jhsa.2018.04.023. Epub 2018 Jun 11.
4
The new era of cost analysis in spine surgery utilizing time-driven activity based costing: a systematic review and introduction of an enabling technology value index.利用时间驱动作业成本法的脊柱外科成本分析新时代:一项系统综述及启用技术价值指数的介绍
Spine J. 2025 Mar 1. doi: 10.1016/j.spinee.2025.02.009.
5
Time-driven Activity-based Costing More Accurately Reflects Costs in Arthroplasty Surgery.时间驱动作业成本法能更准确地反映关节置换手术的成本。
Clin Orthop Relat Res. 2016 Jan;474(1):8-15. doi: 10.1007/s11999-015-4214-0.
6
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
A time-driven activity-based costing model to improve health-care resource use in Mirebalais, Haiti.基于时间的作业成本模型,改善海地米拉巴莱的医疗资源使用情况。
Lancet. 2015 Apr 27;385 Suppl 2:S22. doi: 10.1016/S0140-6736(15)60817-0. Epub 2015 Apr 26.
8
Resource utilisation and cost of ambulatory HIV care in a regional HIV centre in Ireland: a micro-costing study.爱尔兰一家地区性艾滋病毒中心门诊艾滋病毒护理的资源利用与成本:一项微观成本核算研究。
BMC Health Serv Res. 2015 Apr 3;15:139. doi: 10.1186/s12913-015-0816-1.
9
Understanding the Economic Impact of an Essential Service: Applying Time-Driven Activity-Based Costing to the Hospital Airway Response Team.了解一项基本服务的经济影响:将时间驱动作业成本法应用于医院气道反应小组。
Anesth Analg. 2022 Mar 1;134(3):445-453. doi: 10.1213/ANE.0000000000005838.
10
Time-driven activity-based costing of multivessel coronary artery bypass grafting across national boundaries to identify improvement opportunities: study protocol.基于时间驱动作业成本法的跨国多支冠状动脉搭桥术成本核算以识别改进机会:研究方案
BMJ Open. 2015 Aug 25;5(8):e008765. doi: 10.1136/bmjopen-2015-008765.

引用本文的文献

1
Neutrophil extracellular traps and interleukin-1β in cystic fibrosis lung disease.中性粒细胞胞外诱捕网与白细胞介素-1β在囊性纤维化肺病中的作用
Front Immunol. 2025 Jul 28;16:1595994. doi: 10.3389/fimmu.2025.1595994. eCollection 2025.

本文引用的文献

1
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one allele: 144-week interim results from a 192-week open-label extension study.在至少携带一个 F508del 等位基因的囊性纤维化患者中,elexacaftor/tezacaftor/ivacaftor 的长期安全性和疗效:一项为期 192 周的开放标签扩展研究的 144 周中期结果。
Eur Respir J. 2023 Dec 7;62(6). doi: 10.1183/13993003.02029-2022. Print 2023 Dec.
2
Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis.在有商业保险的囊性纤维化患者中,开始使用 elexacaftor/tezacaftor/ivacaftor 前后的真实世界结局和直接护理成本。
J Manag Care Spec Pharm. 2023 Jun;29(6):599-606. doi: 10.18553/jmcp.2023.29.6.599.
3
Factors associated with frequent high-cost individuals with cystic fibrosis and their healthcare utilization and cost patterns.与囊性纤维化频繁高额费用个体及其医疗利用和费用模式相关的因素。
Sci Rep. 2023 Jun 1;13(1):8910. doi: 10.1038/s41598-023-35942-7.
4
Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population.分析依利卓(elexacaftor/tezacaftor/ivacaftor)在商业保险人群中对总医疗成本和其他医疗资源利用的使用和影响。
J Manag Care Spec Pharm. 2022 Jul;28(7):721-731. doi: 10.18553/jmcp.2022.28.7.721.
5
Worldwide rates of diagnosis and effective treatment for cystic fibrosis.全球囊性纤维化的诊断和有效治疗率。
J Cyst Fibros. 2022 May;21(3):456-462. doi: 10.1016/j.jcf.2022.01.009. Epub 2022 Feb 4.
6
Understanding the cost of care of type 2 diabetes mellitus - a value measurement perspective.理解 2 型糖尿病的治疗费用——从价值衡量的角度。
BMJ Open. 2022 Jan 13;12(1):e053001. doi: 10.1136/bmjopen-2021-053001.
7
Healthcare resource utilization and costs among children with cystic fibrosis in the United States.美国囊性纤维化患儿的医疗资源利用情况及费用
Pediatr Pulmonol. 2021 Sep;56(9):2833-2844. doi: 10.1002/ppul.25535. Epub 2021 Jul 7.
8
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One Allele.一项评估 elexacaftor/tezacaftor/ivacaftor 在至少携带一个突变等位基因的囊性纤维化 6 至 11 岁儿童中的疗效和安全性的 3 期、开放性标签研究。
Am J Respir Crit Care Med. 2021 Jun 15;203(12):1522-1532. doi: 10.1164/rccm.202102-0509OC.
9
An evaluation of healthcare utilization and clinical charges in children and adults with cystic fibrosis.囊性纤维化患儿和成人的医疗利用和临床费用评估。
Pediatr Pulmonol. 2021 May;56(5):928-938. doi: 10.1002/ppul.25251. Epub 2021 Feb 23.
10
Entering the era of highly effective modulator therapies.迈入高效调节剂治疗时代。
Pediatr Pulmonol. 2021 Feb;56 Suppl 1:S79-S89. doi: 10.1002/ppul.24968.